Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
The Chief Compliance Officer will be responsible for the design, implementation, oversight, and enforcement of policies and practices to ensure compliance with all applicable laws, rules, and regulations. They will partner with other senior leaders to establish, model, and reinforce the highest standards of ethical behavior and conduct while providing expertise, consultation and assessments in matters related to compliance, audit, and risk. They will implement and oversee company-wide programs reflecting industry best practice for compliance monitoring, reporting, risk assessment, and remediation.
Essential Job Functions
- Establish and direct Kura Oncology’s compliance strategy by identifying and assessing compliance risks in partnership with the Executive Team and other members of senior management.
- Provide insight and direction to the Executive Team regarding the overall development and implementation of the Compliance Program in their respective areas of responsibility to mitigate compliance risks.
- Partner with senior leadership to maintain and further develop a strong culture of ethics and compliance, including personal accountability at all levels in the organization.
- Report to the Board of Directors and Executive Team regarding the Compliance Program and material compliance related developments, highlighting key issues and recommending solutions.
- Establish and direct periodic risk assessments and conduct related ongoing monitoring activities of the Compliance Program, s well as stay abreast of industry and enforcement developments, and recommend policy or procedure modifications when necessary.
- Foster a culture of ethical behavior and integrity within the organization, encouraging employees to report concerns without fear of retaliation.
- Develop training programs and learning platforms for all applicable disciplines and functional areas including but not limited to the company's business ethics and compliance policies and procedures.
- Maintain current awareness of laws, regulations, emerging trends, proposed regulations/guidelines and industry best practices in the regulatory compliance arena.
- Develop and lead the investigative capabilities of the organization in close collaboration with Legal, HR and other functions as appropriate. Investigate allegations of violations of policy or misconduct; conduct/coordinate investigations; communicate findings to the appropriate senior leadership and Board Committee, as necessary. Establish in collaboration with HR appropriate, fair, and equitable consequence management for confirmed violations.
Job Requirements
- 15+ years of relevant compliance and industry experience.
- Juris Doctor (J.D.) or equivalent international degree preferred, with active membership in a Bar Association or equivalent body.
- Minimum of 15 years of experience supporting publicly traded, commercial stage pharmaceutical companies to deliver at scale and within ethical and compliance boundaries. Proven track record of identifying, raising, and solving challenging compliance and ethics issues.
- Experience building best-in-class ethics and compliance programs.
- Demonstrated strong track record of partnering with business management to provide guidance and implementation of effective compliance processes.
- Demonstrated experience driving a culture of ethics and compliance that positively informs people’s actions and decisions. Experience establishing ethics and compliance guidelines and standard operating procedures.
The base range is $336,250 - $363,660 aper year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
What We Do
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Our pipeline includes tipifarnib, a farnesyl transferase inhibitor, currently in a registration-directed clinical trial and KO-539, a menin-MLL inhibitor, currently in a Phase 1/2A clinical trial.
For additional information, please visit our website at www.kuraoncology.com.
